Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences (NYSE:RCUS) has completed patient enrollment for its Phase 3 STAR-221 trial. This trial evaluates the combination of domvanalimab, an anti-TIGIT antibody, with zimberelimab and chemotherapy for treating advanced metastatic upper gastrointestinal (GI) adenocarcinomas. The significance of this trial lies in its potential to introduce the first anti-TIGIT antibody treatment to the market for this patient demographic. Earlier Phase 2 EDGE-Gastric study results showed promising efficacy, with a median progression-free survival (PFS) of 12.9 months and nearly 60% achieving PFS at 12 months without unexpected safety issues. The readout for the Phase 3 trial is anticipated soon.

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in innovative cancer treatments, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event, set to take place in Miami Beach, FL, will feature a fireside chat with Arcus' management team on June 12th, 2024, at 10:00am ET. A live webcast of the discussion will be accessible via the 'Investors & Media' section of the company's website, with a replay available post-event.

Gilead Sciences and Arcus Biosciences announced significant findings from Cohort B of the ARC-9 study. The combination of etrumadenant and zimberelimab with FOLFOX chemotherapy and bevacizumab (EZFB) demonstrated a 63% reduction in the risk of death and a 73% reduction in disease progression compared to regorafenib in third-line metastatic colorectal cancer (mCRC) patients. The data showed a median overall survival of 19.7 months for EZFB, compared to 9.5 months for regorafenib. The findings will be presented at the 2024 ASCO Annual Meeting. The trial included 112 patients and showed a favorable safety profile for the EZFB regimen.

Gilead Sciences and Arcus Biosciences have announced significant results from Cohort B of the ARC-9 Phase 1b/2 study. The study tested a combination regimen including etrumadenant, zimberelimab, FOLFOX chemotherapy, and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC) patients. The EZFB regimen reduced the risk of death by 63% and disease progression by 73% compared to regorafenib. Median overall survival was 19.7 months for EZFB versus 9.5 months for regorafenib. Additionally, the EZFB regimen had a favorable safety profile with fewer treatment-emergent adverse events leading to discontinuation compared to regorafenib. These findings were presented at the ASCO Annual Meeting and highlight the potential of this combination regimen as a treatment option for mCRC patients.

Gilead Sciences and Arcus Biosciences announced positive results from the Phase 2 EDGE-Gastric study, which evaluated the combination of domvanalimab, zimberelimab, and chemotherapy in treating upper GI cancers. Results showed a median progression-free survival (PFS) of over one year, with a 12-month PFS rate of nearly 60%. The regimen demonstrated consistent objective response rates and was well-tolerated, with no unexpected safety signals. These findings support the ongoing Phase 3 STAR-221 study, which aims to confirm these results and potentially bring the first anti-TIGIT combination therapy to market for upper GI cancers. Data will be presented at the ASCO Annual Meeting.

Gilead Sciences and Arcus Biosciences announced promising results from the Phase 2 EDGE-Gastric study evaluating domvanalimab plus zimberelimab and chemotherapy in treating upper gastrointestinal (GI) cancers. The updated data show a median progression-free survival (PFS) beyond one year, surpassing historical benchmarks for similar treatments. Nearly 60% of patients achieved 12-month PFS. The ongoing Phase 3 STAR-221 study aims to further validate these results. The combination therapy was well-tolerated with a safety profile consistent with the individual components. These outcomes support the potential for this combination to address unmet needs in upper GI cancer treatment.

Arcus Biosciences announced that its Compensation Committee granted three new employees options to purchase a total of 16,300 shares of the company's common stock at an exercise price of $16.28 per share. The closing price on May 23, 2024, determined this amount.

Additionally, the company awarded restricted stock units to acquire a total of 8,150 shares. These equity awards align with the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under the “inducement exception” provided by NYSE Rule 303A.08.

Arcus Biosciences, Inc. announced the grant of employment inducement options and restricted stock units to new employees. The total grant includes 141,100 shares of common stock options and 70,555 restricted stock units. The awards were issued under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020.

Arcus Biosciences, Inc. (NYSE:RCUS) reported financial results for Q1 2024 and provided a pipeline update focusing on TIGIT, adenosine axis, HIF-2a, AXL, and PD-1 molecules targeting lung, gastrointestinal, and kidney cancers. Key updates include data presentations at ASCO, Phase 3 studies enrollment, and expansion cohorts for casdatifan in ccRCC. With $1.1 billion in cash, Arcus is well-positioned for pipeline advancement. Financially, Q1 2024 saw increased revenues, R&D expenses, and cash reserves to fund operations into 2027.